20240018480. ENHANCEMENT OF EXTRACELLULAR VESICLE PRODUCTION BY LYSOSOME INHIBITOR simplified abstract (ExoTop Theragnostics Inc.)
Contents
ENHANCEMENT OF EXTRACELLULAR VESICLE PRODUCTION BY LYSOSOME INHIBITOR
Organization Name
Inventor(s)
ENHANCEMENT OF EXTRACELLULAR VESICLE PRODUCTION BY LYSOSOME INHIBITOR - A simplified explanation of the abstract
This abstract first appeared for US patent application 20240018480 titled 'ENHANCEMENT OF EXTRACELLULAR VESICLE PRODUCTION BY LYSOSOME INHIBITOR
Simplified Explanation
The patent application describes methods and systems for enhancing the production of high-quality extracellular vesicles (EVs) from mammalian cells. These methods involve culturing the cells in a chemically-defined protein-free (CDPF) medium and adding a lysosome inhibitor to increase EV production. The CDPF medium may also be supplemented with additives.
- Methods and systems for improving the production of extracellular vesicles (EVs) from mammalian cells are provided.
- The methods involve culturing the cells in a chemically-defined protein-free (CDPF) medium.
- A lysosome inhibitor is added to the medium to enhance EV production.
- The CDPF medium may be supplemented with additives to further improve EV production.
Potential applications of this technology:
- Biomedical research: The enhanced production of high-quality EVs can facilitate studies on intercellular communication, biomarker discovery, and drug delivery.
- Diagnostic tools: EVs can serve as biomarkers for various diseases, and the increased production of high-quality EVs can improve the accuracy and sensitivity of diagnostic tests.
- Therapeutic applications: EVs have shown potential in regenerative medicine, cancer therapy, and immune modulation. The enriched production of high-quality EVs can enhance the efficacy of these therapeutic approaches.
Problems solved by this technology:
- Low yield of EVs: The methods described in the patent application address the issue of low EV production by providing a culture medium and lysosome inhibitor that promote increased EV production.
- Contamination and impurities: The chemically-defined protein-free medium reduces the risk of contamination and ensures the production of high-quality EVs.
Benefits of this technology:
- Increased production of high-quality EVs: The methods and systems described in the patent application can significantly enhance the yield and quality of EVs, providing researchers and clinicians with a valuable resource for various applications.
- Standardization and reproducibility: The use of chemically-defined protein-free medium and lysosome inhibitor allows for better control and reproducibility of EV production, ensuring consistent results across different experiments and studies.
- Cost-effectiveness: The methods described in the patent application utilize a chemically-defined protein-free medium, which can be more cost-effective compared to traditional culture media containing animal-derived components.
Original Abstract Submitted
provided are methods and systems for an enriched production of high-quality extracellular vesicles (evs) from a mammalian cell. in some cases, the methods may comprise culturing the cell in a chemically-defined protein-free (cdpf) medium with the addition of a lysosome inhibitor to increase production of evs. in some cases, the cdpf medium is supplemented with additives.
